Mice receiving the treatment produced their own monoclonal antibodies and survived infection with the life-threatening pathogen Pseudomonas aeruginosa.
A new method stimulates B cells to make human antigen-specific antibodies, obviating the need for vaccinating blood donors or hunting for rare B cells.
Previous flavivirus infection could help explain the severity of symptoms in some people infected during the ongoing Zika outbreak, researchers report.
Facing problems of inconsistent, time-consuming, and costly antibody production, some researchers are turning to alternatives to target specific proteins of interest, in the lab and in the clinic.
